Business Wire

New Study Evaluates the Ability of Masimo ORi™ to Help Clinicians Reduce Hyperoxemia in Mechanically Ventilated ICU Patients

Jaa

Masimo (NASDAQ: MASI) announced today the findings of an abstract presented at the 2018 Congress of the French Society of Anesthesia and Resuscitation (SFAR) in Paris in which researchers at CHU Angers in France investigated the ability of Masimo ORi™ (Oxygen Reserve Index) to help clinicians reduce the number of days ICU patients experience hyperoxemia while on mechanical ventilation.1 ORi, available outside the U.S., is a noninvasive and continuous parameter intended as a relative indicator of a patient’s oxygen reserve during moderate hyperoxia (partial pressure of oxygen in arterial blood [PaO2] in the range of 100 to 200 mmHg). ORi can be trended and has optional alarms to notify clinicians of changes in oxygenation.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180930005016/en/

Masimo Root® with Radical-7®, ORi™, and RD rainbow SET™ Sensor (Photo: Business Wire)

Masimo Root® with Radical-7®, ORi™, and RD rainbow SET™ Sensor (Photo: Business Wire)

Noting that hyperoxemia can lead to patient morbidity and mortality in ICU patients, and that oxygen saturation (SpO2) cannot detect hyperoxemia, Dr. Brochant and colleagues sought to evaluate whether ORi might be useful in helping clinicians determine when to reduce the fraction of inspired oxygen (FiO2) during oxygen therapy, so as to avoid hyperoxemia. In this initial analysis, the first 131 patients in the study, whose data were collected between May 2017 and March 2018, were randomly assigned into an ORi and a control group. In the ORi group, FiO2 was reduced if ORi was > 0. In the control group, the FiO2 level was adjusted according to SpO2. Clinicians recorded blood gas results, episodes of atelectasis, and the length of time spent on mechanical ventilation, for up to 28 days. The principal point of comparison was the proportion of ventilated days with hyperoxemia.

The researchers found that the percentage of days with hyperoxemia was significantly lower in the ORi group: median 14% [interquartile range 0-31%], vs. 29% [IQR 11-50%] in the control group, p=0.005. Average daily PaO2 and FiO2 values were not significantly different between the two groups, suggesting that FiO2 was not systematically lowered in the ORi group. The average number of days without ventilation and median time spent in the ICU were also not significantly different.

The researchers concluded that the use of ORi may help clinicians reduce the percentage of days with hyperoxemia, that analysis of the full group of patients may allow assessment of its effect on the occurrence of atelectasis, and that additional studies may be useful in evaluating the impact of this monitoring on the morbidity and mortality of patients.

ORi has not received FDA 510(k) clearance and is not available for sale in the United States.

@MasimoInnovates | #Masimo

Reference

  1. Brochant A, Dupre P, Gaillard T, Lemarie P, Gergaud S, and Lasocki S. “ORi pour moins d’hyperoxie en reanimation.” Proceedings from SFAR 2018, Paris, France. #R244.

About Masimo

Masimo (NASDAQ: MASI) is a global leader in innovative noninvasive monitoring technologies. Our mission is to improve patient outcomes and reduce the cost of care. In 1995, the company debuted Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry, which has been shown in multiple studies to significantly reduce false alarms and accurately monitor for true alarms. Masimo SET® has also been shown to help clinicians reduce severe retinopathy of prematurity in neonates,1 improve CCHD screening in newborns,2 and, when used for continuous monitoring with Masimo Patient SafetyNet™ in post-surgical wards, reduce rapid response activations and costs.3,4,5 Masimo SET® is estimated to be used on more than 100 million patients in leading hospitals and other healthcare settings around the world,6 and is the primary pulse oximetry at 9 of the top 10 hospitals listed in the 2018-19 U.S. News and World Report Best Hospitals Honor Roll.7 In 2005, Masimo introduced rainbow® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously could only be measured invasively, including total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), Pleth Variability Index (PVi®), and more recently, Oxygen Reserve Index (ORi™), in addition to SpO2, pulse rate, and perfusion index (Pi). In 2014, Masimo introduced Root®, an intuitive patient monitoring and connectivity platform with the Masimo Open Connect® (MOC-9®) interface, enabling other companies to augment Root with new features and measurement capabilities. Masimo is also taking an active leadership role in mHealth with products such as the Radius-7® wearable patient monitor, iSpO2 ® pulse oximeter for smartphones, and the MightySat™ fingertip pulse oximeter. Additional information about Masimo and its products may be found at www.masimo.com. Published clinical studies on Masimo products can be found at http://www.masimo.com/evidence/featured-studies/feature/.

ORi has not received FDA 510(k) clearance and is not available for sale in the United States.

The use of the trademark Patient SafetyNet is under license from University HealthSystem Consortium.

References

  1. Castillo A et al. Prevention of Retinopathy of Prematurity in Preterm Infants through Changes in Clinical Practice and SpO2 Technology. Acta Paediatr. 2011 Feb;100(2):188-92.
  2. de-Wahl Granelli A et al. Impact of pulse oximetry screening on the detection of duct dependent congenital heart disease: a Swedish prospective screening study in 39,821 newborns. BMJ. 2009;Jan 8;338.
  3. Taenzer AH et al. Impact of Pulse Oximetry Surveillance on Rescue Events and Intensive Care Unit Transfers: A Before-And-After Concurrence Study. Anesthesiology. 2010; 112(2):282-287.
  4. Taenzer AH et al. Postoperative Monitoring – The Dartmouth Experience. Anesthesia Patient Safety Foundation Newsletter. Spring-Summer 2012.
  5. McGrath SP et al. Surveillance Monitoring Management for General Care Units: Strategy, Design, and Implementation. The Joint Commission Journal on Quality and Patient Safety. 2016 Jul;42(7):293-302.
  6. Estimate: Masimo data on file.
  7. http://health.usnews.com/health-care/best-hospitals/articles/best-hospitals-honor-roll-and-overview.

Forward-Looking Statements

This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, among others, statements regarding the potential effectiveness of Masimo ORi. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our assumptions regarding the repeatability of clinical results; risks related to our belief that Masimo's unique noninvasive measurement technologies, including Masimo ORi, contribute to positive clinical outcomes and patient safety; risks related to our belief that Masimo noninvasive medical breakthroughs provide cost-effective solutions and unique advantages; as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission ("SEC"), which may be obtained for free at the SEC's website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.

Contact information

Masimo
Evan Lamb, 949-396-3376
elamb@masimo.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Moldova Citizenship-by-Investment Program Completes First Successful Application21.5.2019 12:07:00 EESTTiedote

As concessionaire of the Moldova Citizenship-by-Investment (MCBI) program, Henley & Partners is pleased to note the successful completion of the first citizenship-by-investment application in the country. Henley & Partners has over 20 years of experience in strategic consulting, working with sovereign states around the globe in the design, set-up, and operation of the world’s most respected investment migration programs. The completion of the first citizenship-by-investment application process in Moldova clearly illustrates the features that are at the core of the MCBI program: impressive efficiency and a firm commitment to best practice. Within a three-month window, applicants are thoroughly screened in a multi-stage due diligence process that ensures only highly credible international investors are granted Moldovan citizenship. There are currently over 30 applications in process, which is a testament to the international investment community’s growing appreciation of the value of the

comforte AG Launches New Payments Industry Data Security Solution21.5.2019 11:50:00 EESTTiedote

comforte AG today announced its Data Security Solution and Practice for the Payments Industry. The solution is making its debut at Card Forum 2019, the annual gathering of card and payment executives from the industry’s leading issuers, networks, retailers and innovators. Card Forum 2019 is being held this week in New Orleans. comforte AG has over a decade of history working with payment service providers (PSPs) to achieve compliance with data security regulations, in particular PCI DSS, as well as with more recent legislation such as the EU's General Data Protection Regulation (GDPR) or the upcoming California Consumer Privacy Act (CCPA). Our new solution will provide PSPs with enterprise-grade data security that not only fulfills key requirements of existing regulations, but will also help them to prepare for PSD2, which comes into effect in September of this year. PSD2 and open banking offer PSPs numerous opportunities to generate additional revenue, reduce costs, and increase marke

Lion/Gem Luxembourg 3 S.a.r.l. Announce Second Quarter Results for FY 201921.5.2019 11:00:00 EESTTiedote

The Second Quarter Results for FY19 (to 30 September 2019) for Lion/Gem Luxembourg 3 S.a.r.l. (associated with Young’s Seafood Limited) will be made available on our Investor Relations website on May 21, 2019. The Second Quarter Results for FY19 call for investors that accompanies this information is scheduled to take place at 13:00 BST on May 21, 2019. The Second Quarter covers the quarter to 30 March 2019; the financial year end for Lion/Gem Luxembourg 3 S.a.r.l. is September 30, 2019. For further information: If you are an investor or a potential investor in the 8¼%/ 9% Senior PIK Notes due 2019, of Lion/Gem Luxembourg 3 S.a.r.l., and would like access to this information, please register your interest on our Investor Relations website: https://youngsseafood.co.uk/investors/. If you have any questions about the registration process or need further information, please do not hesitate to contact Nicholas Donnelly, Communications Manager at Young’s Seafood: nicholas.donnelly@youngsseaf

Arthur D. Little: Nord Stream 2 Provides Economic Benefits, Generates Innovation and Helps to Develop Contractors’ Businesses21.5.2019 11:00:00 EESTTiedote

The second part of a recent report from Arthur D. Little (ADL) – “Nord Stream 2 economic impact in the construction phase” – analyzes the economic effects (job creation and GDP) of the ongoing project to build two new gas pipelines from Russia to Germany. The report, which is a follow-up to an earlier report created in 2017, analyzes the current status of project investment and concludes that the total economic benefit to the European Union (EU) represents €9.9 billion for building the pipelines. In comparison to the first report (2017), which was carried out in the procurement phase, more than twice as much CAPEX has now been committed and spent in several EU and non-EU countries now that the project is in the middle of construction. More than 1,000 contractors from all over Europe and Russia are contributing to the realization of the project. This includes both large international firms providing materials or construction services and small enterprises providing expert services. Furt

1 In 10 Banks Will Disappear over the Next 5 Years, According to A.T. Kearney21.5.2019 11:00:00 EESTTiedote

A ten-year study from global management consultancy A.T. Kearney has found that the profit of European retail banks/divisions is at an all-time high, driven by a positive economic environment and lower risks (risk costs relative to total income at lowest level 5% compared to 12% in 2008). Yet, the topline stagnates at (+ 1% in western Europe). A.T. Kearney’s ‘Retail Banking Radar 2019’ analyzes data from 92 banks across Europe and found that despite continued strong growth in volumes, income remains weak with a dramatic drop in income per client (-1.1% 2018 vs 2017; -11% 2018 vs 2008). Meanwhile, a quarter (24.6%) of bank branches across Europe has closed since 2008. The study shows that the industry faces a critical transformation amidst rising consumer demand for digital banking and the growing possibilities of open banking, revealing four key areas: Redefine target operating models, accelerate cost reduction and introduce new agile ways of working Rebalance the organization both in

EURid Q1 2019 Progress Report Now Available21.5.2019 11:00:00 EESTTiedote

Today EURid released its Q1 2019 Progress Report, sharing its quarterly statistics and developments. Highlights include: The quarter posted a renewal rate of 78.2%; The top country for growth for the quarter is Ireland, followed by Sweden and Portugal, which remains in the TOP 3 after leading in Q4 2018; The top ten countries with the most .eu registrations are Germany (984 311), the Netherlands (475 514), France (328 863), Poland (265 807), Italy (265 060), the United Kingdom (188 505), Czech Republic (157 804), Belgium (142 756), and Spain (120 189); Developments throughout the quarter also included: Further support to the Uganda Borehole project; The continuation of the Co-funded Marketing Programme for .eu accredited registrars until 2022, following an in-depth assessment by an external party and the introduction of several procedural refinements. View EURid’s Q1 2019 Progress Report About EURid EURid is the not-for-profit organisation that operates the .eu and .ею top-level domain

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme